Key result
Higher NT-proBNP target attainment linked to ~11% lower risk of hospitalization or death.
Why the study?
Does a higher proportion of longitudinal visits achieving an NT-proBNP target <=1000 pg/mL reduce subsequent all-cause hospitalization or death in patients with HFrEF?
Cohort (n=324)
Does a higher proportion of longitudinal visits achieving an NT-proBNP target <=1000 pg/mL reduce subsequent all-cause hospitalization or death in patients with HFrEF?
While higher longitudinal attainment of NT-proBNP <=1000 pg/mL over 180 days predicts lower risk of hospitalization or death in HFrEF, it offers no significant incremental prognostic value over the single most recent NT-proBNP value.
Answers are grounded in this paper and cite their sources.
Longitudinal NT-proBNP target attainment warrants no immediate clinical adoption in HFrEF; leaves open its added prognostic value.
Serial N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements are prognostic in heart failure with reduced ejection fraction (HFrEF), but the prognostic significance of longitudinal target attainment remains uncertain. We performed a secondary 180-day landmark analysis of the GUIDE-IT trial among participants with at least two NT-proBNP measurements through day 180 and follow-up beyond the landmark. The analytic cohort was restricted to participants who remained event-free according to the broad raw-record endpoint and under observation at the 180-day landmark. The exposure was the proportion of pre-landmark visits with NT-proBNP ≤1000 pg/mL, modeled per 10% increase and as ≥50% versus <50% attainment. The outcome was time to first recorded all-cause hospitalization or death. Cox models adjusted for age, sex, treatment arm, log2-transformed baseline NT-proBNP, New York Heart Association class, atrial fibrillation, and kidney disease. Among 324 participants, 155 experienced hospitalization or death; complete-case models included 319 participants and 154 events. Each 10% increase in target attainment was associated with lower risk (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.84-0.96; P=0.001), as was ≥50% versus <50% attainment (HR 0.44, 95% CI 0.27-0.71; P<0.001). Target attainment improved model fit beyond clinical characteristics and baseline NT-proBNP (likelihood-ratio P<0.001), but not after inclusion of the most recent pre-landmark NT-proBNP measurement (HR 0.97 per 10% increase, 95% CI 0.90-1.06; P=0.51). Greater longitudinal target attainment was associated with lower subsequent risk, although its prognostic information substantially overlapped with the most recent NT-proBNP measurement.
No takes yet. Share an insight, caveat, or question.
Nyirenda et al. (2026) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=324). Proportion of pre-landmark visits with NT-proBNP <=1000 pg/mL (modeled per 10% increase and as >=50% vs <50% attainment) vs. <50% NT-proBNP target attainment (or per 10% lower attainment) was evaluated on Time to first recorded all-cause hospitalization or death (HR 0.89, 95% CI 0.84-0.96, p=0.001). Each 10% increase in longitudinal NT-proBNP <=1000 pg/mL target attainment was associated with lower risk of all-cause hospitalization or death.
Synapse has enriched 10 related papers. Consider them for comparative context: